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Oral glucose tolerance test
Background: The long-term prognosis of coronary artery disease (CAD) patients with insulin resistance has not
been fully examined. In this study, we investigated the influence of postload hyperinsulinemia (PHI) after a
75-g oral glucose tolerance test (OGTT), on the long-term prognosis of CAD patients.
Methods: All study patients were diagnosed as having CAD by coronary angiography. The OGTT was performed
for all patients to establish their blood glucose.Measurement of serum insulinwas also performed simultaneous-
ly. Patients with 2-h insulin level of ≥64 mU/l after the OGTT were included in the postload hyperinsulinemia
(PHI) group, and the others were included in the non-PHI group. The prognosis of 208 patients (96 from the
PHI group and 112 from the non-PHI group) was retrospectively investigated. Study end points were the
composite of death from any cause, unexpected hospitalization for heart failure, new-onset ACS, angina pectoris
requiring PCI or CABG, cerebrovascular disease (CVD), and peripheral artery disease (PAD). Variables were
compared using Kaplan–Meier analysis and the log-rank tests.
Results: The mean follow-up period was 78.7 months. Cardiovascular events including death were 40.6% in the
PHI group and 23.2% in the non-PHI group (log-rank p = 0.0144). CVD, PCI, and CABG occurred continuously
from early to late stage of follow-up in the PHI group compared with the non-PHI group.
Conclusions: The present study showed that the prognosis of CHD patients with PHI was poor. Thus, it is
important to pay attention to these conditions for improving the prognosis of CAD patients.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The incidence of coronary artery disease (CAD) is approximately
three times more likely in diabetes mellitus (DM) patients than in
non-DM patients [1]. Because previous studies have found that glucose
intolerance occurs in approximately two third of patients with acute
myocardial infarction [2], impaired glucose tolerance (IGT) can be
considered as a major coronary risk factor. Hyperinsulinemia, one of
the conditions of abnormal glucose metabolism, significantly affects
atherosclerosis development [3–6]. Cardiovascular complications
could develop in DM patients even during the pre- or early stage
of diabetes. Many of patients of this status have insulin resistance.
However, the prognosis of CAD patients with insulin resistance has
not been fully investigated.liability and freedom from bias
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nd Ltd. This is an open access ai
rticleIn this study, we examined the prognosis of CAD patients with
insulin resistance using postload hyperinsulinemia (PHI), which was
defined as 2-h serum insulin level of ≥64 mU/l after the oral glucose
tolerance test (OGTT).
2. Methods
We investigated the prognosis of 208 CAD patients who were
diagnosed with CAD by their first coronary angiography at our hospital
between April 2000 and December 2010. CAD included acute coronary
syndrome (ACS), stable angina pectoris (SAP), and coronary spastic
angina (CSA). ACS was diagnosed by chest pain together with ST
segment changes on ECG and angiographically significant coronary
artery stenosis or occlusion with thrombus. CSA was angiographically
total or subtotal occlusion after an intracoronary infusion of acetylcho-
line. SAPwas angiographically≥75% coronary artery stenosis according
to the American Heart Association (AHA) category. Patients' diabetic
conditions were not available on admission, but all had no history of
treatment of diabetes. Fasting blood glucose was b126 mg/dl, and
blood glucose at any time was b200 mg/dl. All patients underwent aunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1






Age (yr) 65.3 ± 1.1 64.8 ± 1.2 ns
Male/female 76/36 78/18 p = 0.0284
BMI 23.1 ± 3.0 24.9 ± 3.0 p b 0.0001
Hypertension (%) 49.1 50.0 ns
Smoking (%) 56.3 45.8 ns
LDL-cholesterol (mg/dl) 126.4 ± 54.3 124.1 ± 32.4 ns
HDL-cholesterol (mg/dl) 46.8 ± 14.2 44.4 ± 14.7 ns
Triglyceride (mg/dl) 108.4 ± 52.2 131.6 ± 64.5 p = 0.0051
Lp (a) (mg/dl) 30.6 ± 32.1 25.6 ± 24.9 ns
RLP-cholesterol (mg/dl) 4.26 ± 3.26 5.19 ± 4.12 p = 0.0389
Statin (%) 69.6 64.6 ns
Data are expressed as n (%) or mean ± SD. BMI, body mass index; LDL, low-density
lipoprotein; HDL, high-density lipoprotein; RLP, remnant-like particle.
Fig. 1. Comparison of the OGTT results between the two groups. The IGT and diabetes rate
were higher in the PHI group than in the non-PHI group.
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were measured before and 1 and 2 h after the OGTT.
All patients diagnosed as having glucose intolerance underwent diet
therapy, and oral antidiabetic drugs were prescribed for diabetic
patients if required. No patient required insulin and had a history of
renal or hepatic disease. All study protocols conformed to the require-
ments of the Declaration of Helsinki.
For ACS patients, height and weight were measured, and blood
samples were obtained after 12 h of fasting and when their clinical
status was stable, i.e., approximately 2 weeks after admission. For all
other patients, height and weight were measured on admission, and
blood samples were obtained after 12 h of fasting on their second day
of admission. Homeostatic model assessment indices (HOMA-R) were
calculated as follows: HOMA-R = [fasting insulin (mU/l) × fasting
serumglucose (mg/dl)] / 405 [7]. Thosewith results≥1.73were consid-
ered to have insulin resistance [8].
Patients were divided into two groups based on their 2-h insulin
level after the OGTT. Those with 2-h insulin levels after the OGTT of
≥64mU/l were included in the PHI group, and the otherswere included
in the non-PHI group [8].
Study end points were the composite of death from any cause and
cardiovascular events including unexpected hospitalization for heart
failure, new-onset ACS, coronary artery restenosis after percutaneous
coronary intervention (PCI), and new-onset angina requiring PCI or
coronary artery bypass graft surgery (CABG), cerebrovascular disease
(CVD; transient ischemic attack, cerebral infarction, cerebral hemor-
rhage, and subarachnoid hemorrhage), and peripheral artery disease
(PAD; aortic aneurysm, arteriosclerosis obliterans, and carotid artery
stenosis). We retrospectively investigated the last consultation day,
event-free period, and details of cardiovascular events. For patients
who consulted with other hospitals, we requested information fromTable 2






FBS (mg/dl) 90.4 ± 18.0 93.3 ± 11.0 ns
1 h BS (mg/dl) 175.0 ± 57.2 196.9 ± 41.5 p b 0.0001
2 h BS (mg/dl) 155.3 ± 71.6 179.3 ± 51.2 p b 0.0001
Fasting insulin (μIU/ml) 5.4 ± 2.5 9.1 ± 9.3 p b 0.0001
1 h insulin (μIU/ml) 42.4 ± 28.7 89.3 ± 67.1 p b 0.0001
2 h insulin (μIU/ml) 41.3 ± 14.2 119.0 ± 65.5 p b 0.0001
HbA1c (%) 5.7 ± 12 5.7 ± 0.4 ns
HOMA-R 1.44 ± 1.63 1.91 ± 1.27 p = 0.023
Insulin resistance (%) 22.3 42.7 p = 0.0014
Pioglitazone (%) 0 1 ns
Hypoglycemic agents (%) 8.0 4.2 ns
Data are expressed as n (%) or mean ± SD. FBS, fasting blood sugar; BS, blood sugar;
HOMA-R, homeostasis model assessment-insulin resistance.these hospitals. Patients with follow-up periods of ≤5 years were
excluded.
3. Statistical methods
Statistical results are expressed as a mean ± standard deviation.
Data were analyzed using the Student's t-test for comparison between
the two groups. The Chi-square test was used for all rate comparisons.
Cumulative end point-free ratios were analyzed using the Kaplan–
Meier method and compared using the log-rank test. Resulting p value
of b0.05 was considered statistically significant. Statistical analyses
were performed using JMP10 software for Macintosh (SAS Institute
Inc., Cary, NC, USA).
4. Results
Clinical characteristic data are shown in Table 1. No significant
differences were identified between the groups in terms of age, rate of
hypertension, and smoking. Significant lipid result data included
remarkably high triglyceride and remnant-like particle cholesterol
(RLP-C) values in the PHI group. Low-density lipoprotein (LDL) choles-
terol, high-density lipoprotein (HDL) cholesterol, Lp (a), and the rate of
statin use at admission were not significant. Table 2 shows the result of
the OGTT. FBS was not different, but 1- and 2-h BS and three insulin
level points were all significantly high in the PHI group compared
with the non-PHI group. HOMA-R, rate of insulin resistance, and
normal/IGT/DM ratio (Fig. 1) were also significantly high in the PHI
group but HbA1c was not. The frequency of use of pioglitazone orTable 3







Heart failure 3 2
ACS 7 4
PCI & CABG 6 17
CVD 5 7
PAD 3 4
Data are expressed as n. ACS, acute coronary syndrome; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass grafting; CVD, cerebrovascular disease; PAD,
peripheral artery disease.
Fig. 2. PHI and 120 month outcome. Kaplan–Meier event-free survival curve.
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groups. Details of cardiovascular events are shown in Table 3. Cardiovas-
cular events occurred in 39 patients, including five deaths, in the PHI
group and 26 patients, including two deaths, in the non-PHI group. In
particular, the number of patients requiring PCI and CABG was 17 in
the PHI group.
Kaplan–Meier survival curves showed that the prognosis was signif-
icantly poorer for the PHI group than for the non-PHI group. Incidence
event rates were 40.6% and 23.2% in the PHI and non-PHI groups,
respectively (log-rank p= 0.0144) (Fig.2). In the PHI group, cardiovas-
cular events occurred immediately after initiation of follow-up. In con-
trast, in the non-PHI group, most events occurred 24 months after the
follow-up. This difference was more marked after approximately
90 months. The occurrence of events over time is depicted in Fig. 3. In
the non-PHI group, almost all events occurred between 30 and
80 months. However, in the PHI group, events occurred from the early
to late stage of follow-up, particularly for those requiring PCI and CABG.Fig. 3. Time series display of cardiovascular events. ACS, acute coronary syndrome; PCI, percuta
disease; PAD, peripheral artery disease.5. Discussion
It has been reported that cardiovascular diseases occur even during
the pre- or early stage of diabetes [2], andmost of them are complicated
by insulin resistance [6]. Therefore, the diagnosis and treatment of
insulin resistance are important to prevent cardiovascular disease and
improve its prognosis. Although the glucose clamp technique is neces-
sary for an accurate diagnosis of insulin resistance, HOMA-R, which is
a simple and easy diagnostic procedure [7], is often generally used.
However, even if HOMA-R is within the normal range, many patients
with postprandial hyperinsulinemia have been detected. In addition,
these patients are believed to have insulin resistance. In this study,
almost all patients in the PHI group were in the pre- or early stage of
diabetes and had insulin resistance. Patients of vasospastic angina
with hyperinsulinemia reportedly have a poor long-term prognosis [9]
. Similarly, the results of this study, comprising ACS, SAP, and CSA
patients, show that the long-term prognosis of patients with PHI was
poor. Kaplan–Meier curves dissociated from the early stage of follow-
up and after 80 months. Occurrence of death, heart failure, ACS, and
PAD did not differ between the two groups; however, that of CVD, PCI,
and CABG was constant from the early stage of follow-up to after
80 months in the PHI group compared with the non-PHI group. It has
been reported that insulin resistance is related to the onset of stroke
and coronary heart disease [10,11]. In this study, occurrence of CVD,
PCI, and CABG led to this difference.
All patients in this study had already developed CAD and were
provided treatment for coronary risk factors. It has been reported that
the development of cardiovascular events can be reduced with the use
of statins in type 2 diabetic patients, even if their diabetes is not well
controlled [12]. Although the usage rate of statin was ≥60% in both
groups in this study, the prognosis of the PHI group was poor. It is
conceivable that insulin resistance led to the development of athero-
sclerotic disease and adversely affected the prognosis of CAD patients.
PHI may be a “residual risk factor” for cardiovascular disease.
In this study, some problems exist in judging the influence of insulin
resistance on atherosclerosis. The control levels of coronary risk factors
were unknown when the cardiovascular events occurred. In addition,
most of the patients in the PHI group were in the pre- or early stage of
diabetes. For these patients, diet was the main treatment, and oralneous coronary intervention; CABG, coronary artery bypass grafting; CVD, cerebrovascular
10 T. Yamasa et al. / IJC Metabolic & Endocrine 5 (2014) 7–10antidiabetic drugs were seldom used. Therefore, it may be believed
that patients' diabetic conditions worsened when the events
occurred. The rate of obesity, triglyceride, and RLP-C levels was sig-
nificantly high in the PHI group. Therefore, it was believed that
many patients had metabolic syndrome in the PHI group. However,
we did not measure adiponectin, which is concerned with the pro-
gression of atherosclerosis [13,14].
Pioglitazone is an insulin sensitizer used for the treatment of type 2
diabetes. It has been reported that pioglitazone reduced cardiovascular
complications in type 2 diabetic patients [15]; however, it does not have
applications for prediabetic patients. In addition, some problems have
been reported with pioglitazone [16,17]. Therefore, it is difficult to
positively recommend this drug to prediabetic patients. Angiotensin-
converting enzyme inhibitors and angiotensin II receptor blockers
have an inhibitory effect on new-onset diabetes and an improving effect
on insulin resistance [18–22]. Therefore, we believe that these drugs
should be prescribed for patients in the pre- or early diabetes if their
condition is complicated by hypertension. Diet therapy and weight
control have an improving effect on insulin resistance, and as such,
they are the basics for treatment of glucose intolerance. UKPDS [23]
that provided intensive blood glucose control for patients with new-
onset type II diabetes improved the long-term prognosis [24]. However,
good results have not yet been reported, even for intensive glucose
control for type II diabetic patients who had already been treated
[25–27]. The results of this study show that the prognosis of patients
complicated with PHI was poor, even if they were in the pre- or early
stage of diabetes. It is important to pay attention to patients with PHI,
even if their blood glucose is normal, or they have IGT level. However,
it is unclear whether intensive control for these conditions improves
the prognosis.
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